Cost‐effectiveness of sodium zirconium cyclosilicate for advanced chronic kidney patients in Singapore.

Introduction: Hyperkalaemia (HK) is prevalent among patients with chronic kidney disease (CKD) and chronic heart failure, especially if they are treated with renin‐angiotensin‐aldosterone system inhibitors (RAASi). This study evaluated the cost‐effectiveness of a newly developed anti‐HK therapy, sodium zirconium cyclosilicate (SZC), to the current standard of care for treating HK in advanced CKD patients from the Singapore health system perspective. Methods: We adapted a global microsimulation model to simulate individual patients' potassium level trajectories with baseline potassium ≥5.5 mmol/L, CKD progression, changes in treatment, and other fatal and non‐fatal events. Effectiveness data was derived from ZS‐004 and ZS‐005 trials. Model parameters were localised using CKD patients' administrative and medical records at the Singapore General Hospital Department of Renal Medicine. We estimated the lifetime cost and quality‐adjusted life years (QALYs) of each HK treatment, and the incremental cost‐effectiveness ratio of SZC. Results: SZC demonstrated cost‐effectiveness with an incremental cost‐effectiveness ratsio of SGD 45 068 per QALY over a lifetime horizon, below the willingness‐to‐pay threshold of SGD 90 000 per QALY. Notably, SZC proved most cost‐effective for patients with less severe CKD who were concurrently using RAASi. Sensitivity analyses confirmed the robustness of the findings, accounting for alternative parameter values and statistical uncertainty. Conclusion: This study establishes the cost‐effectiveness of SZC as a treatment for HK, highlighting its potential to mitigate the risk of hyperkalaemia and optimise RAASi therapy. These findings emphasise the value of integrating SZC into the Singapore health system for improved patient outcomes and resource allocation. Summary at a glance: The use of sodium zirconium cyclosilicate (SZC) can potentially lower the risk of hyperkalaemia among patients with chronic kidney disease and facilitate the optimization of RAASi therapy. This study demonstrated the incremental cost‐effectiveness of SZC relative to usual care (sodium polystyrene sulfonate) from the Singapore healthcare system perspective. [ABSTRACT FROM AUTHOR]